Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic octapeptide analog of somatostatin with a much longer half-life than the natural hormone. FDA-approved for acromegaly, carcinoid tumors, and VIPomas. One of the foundational peptide drugs in endocrinology.
A synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH). One of the longest-studied GH-releasing peptides with a history of FDA approval for pediatric GH deficiency.
Binds to somatostatin receptors (primarily SSTR2 and SSTR5), inhibiting growth hormone, glucagon, and insulin secretion. Reduces splanchnic blood flow and inhibits GI motility and secretion.
Directly stimulates the pituitary gland to produce and release growth hormone through the natural GHRH pathway. Maintains the body's natural feedback mechanisms, reducing the risk of GH excess.
- Acromegaly
- Carcinoid syndrome
- VIPomas
- GI bleeding (variceal)
- Dumping syndrome
- Growth hormone deficiency treatment
- Anti-aging protocols
- Improved sleep
- Body composition improvement
- Recovery enhancement
- Gallstones (common with long-term use)
- GI side effects (diarrhea, nausea)
- Hyperglycemia or hypoglycemia
- Injection site pain
- Bradycardia
- Injection site reactions (redness, swelling)
- Headaches
- Flushing
- Dizziness
- Generally well-tolerated in clinical studies
FDA-approved as Sandostatin (1988, subcutaneous) and Sandostatin LAR (1998, monthly depot). Generic octreotide available. Widely used in endocrinology and oncology.
Previously FDA-approved as Geref for diagnostic use and pediatric GH deficiency (withdrawn from market for commercial reasons, not safety). Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
- Octreotide in the treatment of acromegaly
1990 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.